Hackensack Meridian Health (HMH) has launched a cutting-edge cancer risk and early detection program at its Hennessy Institute for Cancer Prevention and Applied Molecular Medicine, in collaboration with CancerIQ, a precision-health technology company. The initiative aims to improve early cancer diagnosis, treatment, and prevention by integrating advanced technology, genomics, and AI into real-time electronic health record (EHR) workflows. The program includes a CancerIQ tool that assesses personal and family medical histories, along with lifestyle factors, to identify individuals at higher cancer risk and provide personalized early detection and prevention strategies.
The program also incorporates molecular cancer screening techniques like liquid biopsies, which detect cancer at its earliest stages by identifying genetic materials released into the bloodstream. HMH plans to offer this program at its newly established Cancer Center in Totowa, New Jersey, with expansion plans for Clifton by early 2025. According to Andre Goy, chairman and executive director of John Theurer Cancer Center, this initiative opens new avenues for preventing cancer in genetically at-risk individuals and reducing cancer recurrence through early detection.
This initiative aligns with broader trends in precision oncology, where companies like CancerIQ, GE HealthCare, and BAMF Health are advancing personalized treatment through technologies like genetic testing and theranostics. The World Health Organization estimates that 30% to 50% of cancer cases are preventable, and programs like HMH’s could significantly enhance cancer prevention efforts by improving access to genetic testing and personalized care plans.
Click here to read the original news story.